USING ANTI-AMYLOID BETA ANTIBODY IN OPHTHALMIC DISEASES Russian patent published in 2015 - IPC C07K16/18 

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to biotechnology. There are described pharmaceutical compositions for treating ophthalmic diseases associated with pathological abnormalities/changes of visual tissues, especially associated with amyloid-beta related pathological abnormalities/changes of the visual tissues, containing antibodies specifically recognising and binding specific epitopes from the range of β-amyloid proteins. There are also presented methods for reducing the load/plaque count in the retinal gangliocyte layer in a mammal suffering from an analogous ophthalmic disease. Besides, there are presented a method for reducing the total amount of soluble amyloid-β in the mammalian retinal gangliocyte layer, a method for preventing manifestations of the analogous ophthalmic disease, a method of treating or relieving the manifestations of the analogous ophthalmic disease. A method for maintaining or reducing an ocular tension in an animal suffering from the analogous ophthalmic disease. All the methods involve administering the described composition.

EFFECT: invention extends the methods and compositions for diagnosing and treating the amyloid diseases that represent a group of amyloid protein related diseases and disorders, eg Alzheimer disease.

55 cl, 20 dwg, 7 tbl, 18 ex